The metastasis of certain systemic cancers to the brain poses a significant challenge to oncologists and patients alike. Several key modulators in the hostile brain tumor microenvironment promote cancer cell proliferation, apoptosis, metabolism, growth factor signaling, migration and invasion. There is a growing need to understand brain metastases.
The complexity of the blood-brain barrier (BBB) and lack of effective targeted drugs that penetrate BBB is the greatest challenge in treating brain metastases. Consequently, many researchers are experimenting with various in vitro and in vivo models of brain metastases to better understand how these cancers migrate to the brain, and what type of therapeutic molecules penetrate the BBB to reach brain tumor cells.
In this webinar, the featured speaker discusses few of these preclinical models that might impact the clinical development of metastatic brain tumor-specific anticancer drugs.
Join this webinar to learn about the challenges for developing clinically relevant preclinical models for brain cancer.
Dr. Nagendra Ningaraj, Global Senior Director of Scientific Affairs, Aragen Life Sciences, USA
Dr. Nagendra Ningaraj has held progressive leadership roles in preclinical and clinical oncology research and development. He worked at academic centers like the University of Kansas, Cedars-Sinai Medical Center, Mercer University Medical Center, Vanderbilt University Medical Center and the Anderson Cancer Institute. He led research teams on brain tumor and breast cancer biology. He had extensively published in peer-reviewed journals and secured US, EU and Japan patents. He directed the Human Tissue banking and biorepository and New Animal Facility. Later he worked in pharmaceutical companies such as Dr. Reddy’s Labs, Scintilla BioMarc, PPD/ Thermo Fisher Scientific with focus on in vitro diagnostics, clinical pharmacology and toxicology and medicinal chemistry aspects of clinical drug development. He is presently a Global Senior Director of Scientific Affairs at Aragen Life Sciences, USA.Message Presenter
Who Should Attend?
Scientists and business development personnel of pharmaceutical and biotechnology companies and virtual and other CROs involved in IND-enabling preclinical and clinical research activities. Also, academic scientists working on CNS tumor research could be interested.
What You Will Learn
Attendees will learn:
- Challenges of clinically relevant preclinical brain metastasis models
- Role of blood-brain barrier (BBB) in anticancer drug delivery
- Aggressive metastases in the central nervous system (CNS) and the effectiveness of current therapies
- Progress in developing specific models to study metastatic cancers like triple-negative breast cancer, melanomas and lung cancer
- How optimizing these models should improve the clinical impact by understanding the biology of aggressive metastatic tumors in patients
- Selection of metastatic brain cells in murine models
- About genetically engineered mouse models
Aragen Life Sciences
Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. It offers end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, the Company operates through a network of sites located globally with a team of 3000+ scientists and 450+ PhDs. Its expertise and experience have enabled over 450 customers to advance their research programs from discovery through commercialization. Aragen’s innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma, biotech, agrochemical, animal health and performance chemical industries globally. Visit www.aragen.com for more details.